Alembic Pharma Q1 FY27: revenue up 26 percent YoY at Rs 2,150 cr

Revenue Growth 20pctEbitda Margin CompressionResults View source PDF Explain this filing

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.7%Reaction day

₹805.05

prior close

₹808.20

announcement price

In-mkt

timing

Nifty Microcap 250market+0.4%+0.3% vs market

Pharmaceuticals peers, median of 165sector-0.0%+0.8% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.3

10m

+0.6

15m

-0.1

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.7+0.4+0.3-0.0+0.8

Next day

+1.4+1.7-0.4+0.0+1.4

+3.7+2.1+1.6+0.2+3.6

+3.6+2.1+1.4+0.4+3.2

+3.6+2.1+1.5+0.6+3.0

+4.3+1.9+2.4+0.8+3.5

+3.2+2.4+0.8+0.4+2.8

15d

-0.0+3.0-3.0+0.5-0.5

+0.1+3.7-3.7+1.1-1.1

+3.3+1.6+1.8+2.0+1.4

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alembic Pharma's Q1 FY27 (Apr-Jun 2026) consolidated revenue rose about 25.7 percent YoY to Rs 2,149.77 crore. PAT grew about 13.6 percent YoY to Rs 175.33 crore, with EPS of Rs 8.80. However, operating margin compressed to 13.84 percent from 16.03 percent a year ago. Standalone revenue also rose about 25 percent to Rs 1,868.06 crore. Statutory auditor changed from K C Mehta and Co LLP to KKC and Associates LLP, which issued an unqualified review report.

Likely market impact

Strong top-line growth, but margin pressure persists. New auditor and margin recovery will be watched.